• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Is Endometrial Sampling Effective for Preoperative Detection of Uterine Leiomyosarcoma?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Preoperative diagnosis of leiomyosarcoma (LMS) is difficult, as it often mimics the appearance of benign leiomyomas
    • Endometrial sampling detects epithelial endometrial carcinomas, but the predictive value for leiomyosarcoma (LMS) is unknown
  • Kho et al. (Journal of Minimally Invasive Gynecology, 2021) assessed the effectiveness of endometrial sampling for preoperative detection of LMS in women undergoing hysterectomy

METHODS:

  • Retrospective cohort study
  • Data sources (from 2003 to 2015)
    • New York Statewide Planning and Research Cooperative System (SPARCS)
    • New York State Cancer Registry
  • Participants
    • LMS diagnosis
    • Underwent a hysterectomy and a preoperative endometrial sampling within 90 days of surgery
    • Exclusion: Preexisting diagnosis of LMS before the date of endometrial sampling | Had other cancers before the diagnosis of LMS | LMS diagnosed more than 3 months after hysterectomy (and therefore may not have been present at time of endometrial sampling)
  • Exposure
    • Endometrial sampling
  • Primary outcome
    • Missed LMS diagnosis
  • Secondary outcomes
    • Association between missed diagnosis and patient outcomes (e.g., inappropriate surgical approach and survival)

RESULTS:

  • 79 patients with LMS
    • Diagnosed preoperatively: 58.2%
    • Diagnosed postoperatively: 41.8%
    • No significant differences in age, race/ethnicity, bleeding symptoms, or comorbidities between above 2 groups
  • Endometrial sampling
    • With hysteroscopy: 75.9%
    • Without hysteroscopy: 24.1%
  • Endometrial sampling with vs without  hysteroscopy had a higher likelihood of preoperative diagnosis
    • Adjusted risk ratio 3.03 (95% CI, 1.43 to 6.42)
  • Patients were less likely to be diagnosed preoperatively if they had
    • Localized stage (vs distant stage)
      • aRR 0.50 (95% CI, 0.28 to 0.89)
    • Tumor size >11 cm (vs <8 cm)
      • aRR 0.54 (95% CI, 0.30 to 0.99)
  • Supracervical hysterectomy was only performed on patients with LMS diagnosed postoperatively (P=0.002)
    • Preoperatively diagnosed LMS: 0
    • Postoperatively diagnosed LMS: 21.2%
  • All patients diagnosed preoperatively had total/radical hysterectomy at the index surgery

CONCLUSION:

  • LMS was diagnosed preoperatively in 58.2% of patients who underwent endometrial sampling
  • Using hysteroscopy with endometrial sampling was associated with an improved likelihood of preoperative diagnosis
  • Larger tumor size was less likely to result in a preoperative diagnosis possibly due to cavity distortion
  • Patients who had a missed diagnosis had a higher risk of undergoing supracervical hysterectomy, a suboptimal index surgical strategy
  • The authors state

…the additional benefit of hysteroscopy for the detection of LMS, which is a deep muscle tumor, had not been previously shown

Our study addressed this important gap and demonstrated that hysteroscopy used in conjunction with biopsy or D&C improved the likelihood of LMS detection by threefold

Learn More – Primary Sources:

Endometrial Sampling for Preoperative Diagnosis of Uterine Leiomyosarcoma

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Minimally Invasive Hysterectomy for Endometrial Cancer
How Common is Unexpected Uterine Cancer at Hysterectomy?
Is Tamoxifen a Risk Factor for Endometrial Cancer in Women with Endometrial Polyps?
What is the Prevalence of Occult Malignancy During Hysterectomy or Myomectomy for Benign Indications?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site